Horizon Pharma is slated to report Q2 earnings on August 8, 2016.
The company has a history of solid top- and bottom-line outperformance.
I expect a steady sequential revenue ramp in both the primary care and the orphan segment; Pennsaid 2% and Krystexxa hold the most potential for upside surprises.
FY revenue and EBITDA guidance should stay the same.
The company did not make an acquisition in more than six months; the likelihood of a deal being announced is high over the next few months.
Horizon Pharma (NASDAQ: